May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Subtenon Triamcinolone for Refractory Diabetic Macular Edema
Author Affiliations & Notes
  • A. Polito
    Department of Ophthalmology, University of Udine, Udine, Italy
  • P. Lanzetta
    Department of Ophthalmology, University of Udine, Udine, Italy
  • D. Roman Pognuz
    Department of Ophthalmology, University of Udine, Udine, Italy
  • I. Paissios
    Department of Ophthalmology, University of Udine, Udine, Italy
  • F. Bandello
    Department of Ophthalmology, University of Udine, Udine, Italy
  • Footnotes
    Commercial Relationships  A. Polito, None; P. Lanzetta, None; D. Roman Pognuz, None; I. Paissios, None; F. Bandello, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1448. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Polito, P. Lanzetta, D. Roman Pognuz, I. Paissios, F. Bandello; Subtenon Triamcinolone for Refractory Diabetic Macular Edema . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1448.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effect of subtenon injection of triamcinolone acetonide (TA) for the treatment of diabetic macular edema unresponsive to previous laser treatment. Methods: This retrospective, clinical case series included 9 consecutive patients (9 eyes) who received a subtenon injection of 1 ml of 40 mg of TA. Main outcome measures were measurement of foveal thickening (FTH) with optical coherence tomography (OCT), change in Snellen visual acuity (LogMAR equivalent) and intraoculare pressure. Results: Nine eyes completed 1 month, 7 eyes 3 months and 4 eyes 6 months of follow–up. Mean (SD) FTH decreased from 488 (123) µm at baseline to 385 (104) µm, 378 (93) µm and 344 (24) µm at the 1, 3, and 6 month follow up period, respectively. Mean (SD) visual acuity improved from 0.53 (0.22) at baseline to 0.38 (0.14 ), 0.37 (0.18), and 0.33 (0.10) at the 1, 3, and 6 month of follow up, respectively. No change in intraocular pressure occurred. Conclusions: Subtenon TA appears to be a possibly effective and safe treatment in patients with refractory diabetic macular edema, at least in the short term. The simple route of administration and the possibility of multiple injection give interest to this treatment.

Keywords: diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×